Skip to Content

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-09-157: In vivo Cellular and Molecular Imaging Centers (ICMICs) (P50)

    • Release Date: April 13, 2009
    • Application Receipt Date: October 28, 2009, October 28, 2010, October 28, 2011
    • Expiration Date: October 29, 2011
    • Contacts:

      Anne Menkens, Ph.D. ( at 301-496-9531

    The Cancer Imaging Program, and the Division of Cancer Diagnosis and Treatment, at the National Cancer Institute (NCI), invite new or renewal (competing) applications for P50 Research Center Grants for In vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research. ICMIC funding is designed to: (1) support innovative cancer molecular imaging research projects; (2) support unique core facilities; (3) enable the awardees to initiate pilot research in new promising directions; and (4) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.

    • Letters of Intent Receipt Dates: September 28, 2009, September 28, 2010, September 28, 2011
    • No set-aside

    See full description in NIH Guide:PAR-09-157

  • PAR-08-225: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)

    • Release Date: August 03, 2008
    • Application Receipt Date: Standard dates
    • Expiration Date: May 8, 2011
    • Contacts:

      Robert J. Nordstrom,  Ph.D. ( at 301-594-9121

    The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees will form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.

    • No set-aside

    See full description in NIH Guide: PAR-08-225

  • PAR-08-147: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants (R21) (NCI)

    • Release Date: April 15, 2008
    • Expiration Date: April 12, 2011
    • Contacts:

      Barbara Galen, M.S.N., C.R.N.P., C.N.M.T., NCI, Phone: 301-594-5225, Email:
      Lalitha Shankar, M.D., NCI, Phone: 301-496-9531, Email:
      Keyvan Farahani, Ph.D., NCI, Phone: 301-451-2651, Email:

    The goal of this Funding Opportunity Announcement (FOA) is to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) studies, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or Cooperative Groups.

    Mechanism of support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism

    See full description in NIH Guide:PAR-08-147

    For instructions on the inclusion of clinical protocols in the PAR-08-147 application, see NOT-CA-10-019